An overview of the latest in state-of-the-art murine models for prostate cancer

Nascimento-Gonçalves, Elisabete; Seixas, Fernanda; Ferreira, Rita; Colaço, Bruno; Parada, B.; Oliveira, Paula A.

doi:10.1080/17460441.2021.1943354

Cited by 4 publications

(5 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal models enable the study of carcinogenesis pathways and/or the performance of pre-clinical studies to evaluate the efficacy of different chemopreventive and/or therapeutic compounds [ 126 ]. Therefore, rodent models of mammary carcinogenesis may be obtained through the administration of chemical carcinogens to increase the incidence rates of mammary tumors and accelerate mammary cancer development [ 127 ].…”

Section: Nsaids For Breast Cancermentioning

confidence: 99%

Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies

Ferreira,

Faustino-Rocha,

Gaspar

et al. 2024

Vet World

Self Cite

View full text Add to dashboard Cite

Chronic inflammation plays a crucial role in carcinogenesis. High levels of serum prostaglandin E2 and tissue overexpression of cyclooxygenase-2 (COX-2) have been described in breast, urinary, colorectal, prostate, and lung cancers as being involved in tumor initiation, promotion, progression, angiogenesis, and immunosuppression. Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for several medical conditions to not only decrease pain and fever but also reduce inflammation by inhibiting COX and its product synthesis. To date, significant efforts have been made to better understand and clarify the interplay between cancer development, inflammation, and NSAIDs with a view toward addressing their potential for cancer management. This review provides readers with an overview of the potential use of NSAIDs and selective COX-2 inhibitors for breast cancer treatment, highlighting pre-clinical in vitro and in vivo studies employed to evaluate the efficacy of NSAIDs and their use in combination with other antineoplastic drugs. Keywords: breast cancer, chemoprevention, COX-2, cyclooxygenase, experimental studies, NSAIDs.

show abstract

Section: Nsaids For Breast Cancermentioning

confidence: 99%

Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies

Ferreira,

Faustino-Rocha,

Gaspar

et al. 2024

Vet World

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nowadays, several animal models are available for PCa study, namely spontaneous models, chemically-induced, hormonally-induced, implanted, and genetically-modified (34,35) (Figure 1).…”

Section: Which Models Are Available For Studying Prostate Cancer?mentioning

confidence: 99%

Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies

et al. 2022

View full text Add to dashboard Cite

Prostate cancer (PCa) is among the most frequent cancers worldwide. Nowadays, several therapeutic strategies are available for PCa treatment, namely chemotherapy, immunotherapy, radiotherapy, and hormonal therapy. Despite existing therapeutic approaches, in vitro and in vivo models are essential to better understand cancer development and search for more effective therapies, with a positive impact in cancer patient survival and quality of life. Among several models available, the rat model is the one most frequently used, since it shares anatomical, physiological, pathological, and behavioral features with humans. Animal models can be classified as: spontaneous, chemically-induced; hormonally-induced; implantation of cancer cell lines obtained from humans or from the same species, in the place of disease development or in a different place; and genetically-modified models. The chemically-induced models are among the most frequently used for PCa research. This manuscript provides a comprehensive overview of PCa models, presenting their application, advantages, and disadvantages, and their importance for the development of current therapies for prostate cancer.Prostate cancer (PCa) is among the most common cancers in men. In 2020, PCa was the third most diagnosed neoplasia, with 1,414,259 new cases (7.3% of all cancer cases) and 375,304 deaths (1).During the last decades, PCa therapy has seen a remarkable evolution in many sectors, namely chemotherapy, immunotherapy, radiotherapy, and hormonal therapy. New precision medicine strategies and treatments are also suffering massive developments nowadays, also for PCa management, namely new proteomic and genomic technologies, non-coding RNA therapeutics or gene editing technologies (2).Over the decades, different animal and non-animal models have been used to describe PCa morphologically, evaluate its development, set up prognostics, and develop more successful and globally used treatments.This work aimed to review the different models used in PCa research among the decades and highlight their significant contribution to the discovery of various therapies regularly used nowadays to treat men with PCa and significantly improve their lives. Prostate Cancer: An OverviewPCa is a neoplasia that results from the uncontrolled growth of the prostatic gland cells. Almost all PCas are adenocarcinomas. However, histologically, two types can be considered: acinar adenocarcinoma and non-acinar carcinoma. PCa acinar 323

show abstract

“…Animal models that mimic the natural history of human cancers are critical for a better understanding of the mechanisms associated with the development and progression of PCa, without being affected by lifestyle and comorbidities. The choice of an animal model is crucial for the successful translation of experimental data into clinical practice [ 12 ]. In the model of hormonally and chemically induced PCa, male rats exhibit tumors that are hormone-dependent and histologically similar to those in men [ 12 , 13 ], making them a good option for studying prostate carcinogenesis in its early stages.…”

Section: Introductionmentioning

confidence: 99%

“…The choice of an animal model is crucial for the successful translation of experimental data into clinical practice [ 12 ]. In the model of hormonally and chemically induced PCa, male rats exhibit tumors that are hormone-dependent and histologically similar to those in men [ 12 , 13 ], making them a good option for studying prostate carcinogenesis in its early stages.…”

Section: Introductionmentioning

confidence: 99%

Tracking Prostate Carcinogenesis over Time through Urine Proteome Profiling in an Animal Model: An Exploratory Approach

Moreira‐Pais

Nogueira-Ferreira

Reis

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most lethal diseases in men, which justifies the search for new diagnostic tools. The aim of the present study was to gain new insights into the progression of prostate carcinogenesis by analyzing the urine proteome. To this end, urine from healthy animals and animals with prostate adenocarcinoma was analyzed at two time points: 27 and 54 weeks. After 54 weeks, the incidence of pre-neoplastic and neoplastic lesions in the PCa animals was 100%. GeLC-MS/MS and subsequent bioinformatics analyses revealed several proteins involved in prostate carcinogenesis. Increased levels of retinol-binding protein 4 and decreased levels of cadherin-2 appear to be characteristic of early stages of the disease, whereas increased levels of enolase-1 and T-kininogen 2 and decreased levels of isocitrate dehydrogenase 2 describe more advanced stages. With increasing age, urinary levels of clusterin and corticosteroid-binding globulin increased and neprilysin levels decreased, all of which appear to play a role in prostate hyperplasia or carcinogenesis. The present exploratory analysis can be considered as a starting point for studies targeting specific human urine proteins for early detection of age-related maladaptive changes in the prostate that may lead to cancer.

show abstract

An overview of the latest in state-of-the-art murine models for prostate cancer

Cited by 4 publications

References 164 publications

Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies

Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies

Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies

Tracking Prostate Carcinogenesis over Time through Urine Proteome Profiling in an Animal Model: An Exploratory Approach

Contact Info

Product

Resources

About